Filter Results
Filter Results
Integrated Biologics (16) Specialized Modalities (11) Advanced Synthesis (8) Capsules & Health Ingredients (5) Corporate (3)
Media Advisory (43) New Technologies (10) Partnerships (9) Sustainability (3) New Products (2) General (1)
2025 (5) 2024 (21) 2023 (16) 2022 (1)
English (43)
Media AdvisoryX
EnglishX
Showing 1‐20 of 43
Media Advisory
14 Apr 2025
Lonza joins Centre for Continuous Manufacturing and Advanced Crystallisation to Enhance Service Offering
Lonza joined CMAC to enhance its service offering for specialty and enhanced drug product and particle technologies   Lonza will serve as a CMAC Translation to Industry...
Media Advisory
07 Apr 2025
Ethris and Lonza Collaborate to Develop Spray-Dried mRNA Vaccines for Respiratory Disease Prevention
Formulations to be developed at Lonza’s Center of Excellence for bioavailability enhancement and inhaled delivery in Bend (US), in accordance with current Good Manufacturing...
Media Advisory
11 Mar 2025
Exogenus Therapeutics Chooses Lonza to Develop a GMP-Compliant Process to Manufacture Exo-101, its Lead Exosome-Based Candidate
Lonza to develop a GMP-compliant process for Exo-101 manufacturing from its Siena (IT) site Exo-101 has shown safety and efficacy in multiple pre-clinical trials, and...
Media Advisory
06 Mar 2025
Lonza Capsules & Health Ingredients Establishes Center of Applied Sustainability
As part of Lonza Capsules & Health Ingredients’ (CHI) continued focus on sustainability, a new Center of  Applied Sustainability has been established to accelerate...
Media Advisory
13 Jan 2025
Iconovo and Lonza to Collaborate on the Formulation Development of an Intranasal Biologic
Lonza to develop spray-dried formulations for an intranasally-delivered biologic for Iconovo at its Center of Excellence for bioavailability enhancement and inhaled delivery in...
Media Advisory
19 Dec 2024
Lonza Capsules & Health Ingredients Expands Capsule Manufacturing Capacity in India and China
New capsule manufacturing lines added at Lonza Capsules & Health Ingredients (CHI) facilities in Rewari (IN) and Suzhou (CN), highlighting the long-term strategic commitment to...
Media Advisory
03 Dec 2024
Lonza Launches Tailored Offering for Smart Capsules Companies Developing Oral Delivery Solutions for Biologic Drugs
Tailored offering for companies developing smart capsules includes bespoke targeted drug delivery solutions and customized capsule designs for oral biologic drugs Service...
Media Advisory
20 Nov 2024
​​Lonza Announces First GMP Batch Completion at ​Next-Generation Mammalian Manufacturing Facility in Portsmouth (US)
First GMP batch released at Lonza’s next-generation mammalian manufacturing facility in Portsmouth (US)   State-of-the-art technology supports Lonza’s next-generation mammalian...
Media Advisory
04 Nov 2024
Lonza’s Synaffix Collaborates with BigHat Biosciences on the Development of a Machine Learning-Designed ADC
Commercial license to Synaffix technologies follows a series of successful initial preclinical proof of concept studies Collaboration underscores Lonza’s commitment to helping...
Media Advisory
15 Oct 2024
Lonza Completes Expansion of New Drug Product Services Facility in Basel (CH)
Expansion adds a new facility to Lonza’s Drug Product Services (DPS) footprint, supporting clinical and commercial projects through additional quality control (QC) and...
Media Advisory
26 Sep 2024
Lonza Walkersville Commences Expansion of Endotoxin Assay Production Facility
Lonza Walkersville is investing in an expansion of its endotoxin assay production facility The upgraded facility will incorporate sustainable technologies and streamline...
Media Advisory
26 Sep 2024
Acumen Pharmaceuticals Extends Collaboration with Lonza to Add Drug Product Manufacturing of Sabirnetug for Early Alzheimer’s Disease
Agreement builds upon a successful collaboration supporting the manufacture of sabirnetug (ACU193) drug substance (DS) for clinical studies in Alzheimer’s disease Extension to...
Media Advisory
19 Sep 2024
Lonza Launches Innovaform™ Accelerator, the New Innovation and Formulation Center in Colmar (FR)
The new facility will serve as a Center of Excellence for co-innovation with pharmaceutical customers on formulation and encapsulation innovation projects The facility includes...
Media Advisory
05 Sep 2024
​​Lonza Completes Expansion of Microbial Manufacturing Facility in Visp (CH) ​
Expansion adds manufacturing capacity for clinical and commercial supply of microbially-produced biologics The facility is now GMP-qualified for manufacturing...
Media Advisory
15 Aug 2024
UK Government Supports Lonza’s Expansion Plans
Lonza has purchased a plot in Thames Valley Park, with a view to relocating and expanding its primary UK-based Biologics site over the next decade This proposed new site would...
Media Advisory
13 Aug 2024
Champalimaud Foundation Adopts Lonza’s MODA-ES® Platform to Streamline Cell Therapy Manufacturing
MODA-ES® Platform, a next-generation manufacturing execution system for cell and gene therapies, facilitates a cost-effective transition to electronic record-keeping By...
Media Advisory
06 Aug 2024
Lonza Upgrades Clinical Manufacturing Services at Bend (US) Site to Include Bottling and Labeling Capabilities
Lonza Bend (US) upgrades capabilities in early phase clinical manufacturing services with the addition of bottling and labeling equipment New equipment to support bottling of...
Media Advisory
20 Jun 2024
Lonza Launches Enprotect® Size 9 Capsule to Accelerate Pre-Clinical Development of Acid-Sensitive Active Pharmaceutical Ingredients
Lonza launches Capsugel® Enprotect® size 9 capsule to support the evaluation of candidate drugs New size 9 capsule enables pre-clinical testing in rodents, which accelerates...
Media Advisory
29 Apr 2024
Lonza Launches AI-Enabled Route Scouting Service to Accelerate Small Molecule Development
New advanced technology-enabled offering aims to streamline synthetic route identification for novel active pharmaceutical ingredients (APIs) The AI-driven route design...
Media Advisory
17 Apr 2024
Lonza Signs Multiple Renewable Energy Certificate Agreements in the United States
Lonza signs three Renewable Energy Certificate (REC) purchase agreements in the United States (US), supporting the commissioning of additional renewable energy projects
1 2 3 >